Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding
概览
- 阶段
- 不适用
- 干预措施
- Doppler Endoscopic Probe
- 疾病 / 适应症
- Delayed Post-Polypectomy Induced Ulcer Hemorrhage
- 发起方
- VA Office of Research and Development
- 入组人数
- 180
- 试验地点
- 6
- 主要终点
- The proportion of participants with delayed Post-Polypectomy Induced Ulcer (PPIU) bleeds.
- 状态
- 招募中
- 最后更新
- 3个月前
概览
简要总结
The primary specific aim is to perform a randomized controlled trial (RCT) to compare rates of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet drugs or with large ulcers) after snare resection of benign colon polyps.
详细描述
VA Central Office recently opened back research study after suspension from March to Sept 2020 with COVID 19 Severe delayed post-polypectomy induced ulcer (PPIU) bleeding has become a much more common problem with the increased numbers of colonoscopies being performed and with more patients taking anti-coagulants or anti-platelet drugs. Current medical guidelines may reduce bleeding during polypectomy, but are not effective for prevention of delayed bleeding. Empiric closure of PPIU's with clips is not effective because ulcers \> 15 mm cannot be closed, does not treat the underlying artery in the ulcer base, and when the clips often fall off within 7 the underlying artery is exposed. As preliminary results, the investigators studied delayed PPIU bleeds and their prevention, used a Doppler endoscopic probe (DEP) to localize arteries in PPIU's, reported the prevalence which rises significantly as ulcer size increases, and successfully obliterated blood flow with focal treatment. These studies form the basis for this new RCT. The primary specific aim is to perform a RCT to compare rates of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet drugs or with large ulcers) after snare resection of benign colon polyps. Secondary specific aims are to evaluate the natural history and risk factors for delayed PPIU bleeding using univariate and multivariable analyses. This is a RCT performed by the CURE Hemostasis Research Group for high risk patients - those with PPIU's 15 mm in size or greater but not on drugs associated with bleeding; or patients who require anti-coagulants or anti-platelet drugs for treatment of co-morbid conditions and have PPIU's 10 mm or larger. Outpatients, scheduled for screening or surveillance colonoscopies, who give written informed consent and meet entry criteria will be randomized to control/no DEP (medical treatment without PPIU closure) or DEP (as a guide to arterial blood flow detection and focal obliteration of it with hemoclips and/or low power multipolar electrocautery \[MPEC\] probe). Patients will be prospectively followed at 7, 14, and 30 days for bleeding, complications, or unscheduled visits for healthcare after polypectomies.
研究者
入排标准
入选标准
- •Ambulatory patients, 35 years old or more and who are having:
- •elective, outpatient screening
- •surveillance colonoscopy for colon cancer or polyps
- •or being evaluated for abdominal pain or change in bowel habits ---or have a large polyp needing removal by EMR or ESD
- •Clinically the patient has to have a medical indication and recommendation by their primary care physician (PCP) or specialist to take:
- •daily anti-coagulants (Warfarin, low-molecular-weight heparin \[LMWH\] or a newer agent)
- •or an anti-platelet drug (aspirin as 81 mg or more, Clopidogrel, or newer agents) for PPIU's 10-14mm
- •or if not on one of these drugs, they must have a PPIU 15 mm
- •On colonoscopy, they are required to have:
- •benign appearing polyps and for 1 or more PPIU to be 10 mm in size (for the anti-coagulant or anti-platelet groups)
排除标准
- •Inability or unwillingness to give written informed consent or to return to the investigators' medical centers for follow-up (FU) in the next 30 days, in case of delayed bleeding or other complications
- •Intrinsic bleeding disorder with a history of recurrent bleeding either after:
- •surgeries
- •angiography
- •or other invasive procedures
- •Significantly abnormal coagulation tests related to co-morbid liver, hematologic, or infectious disorders and not anti-coagulant drugs, with platelet count \< 100,000; international normalized ratio (INR) \> 1.5; or partial thromboplastin time (PTT) more than 1.5 times normal
- •Inflammatory bowel disease
- •Infectious colitis
- •Idiopathic colitis with a history of recurrent rectal bleeding
- •Recurrent rectal bleeding from another chronic colorectal condition such as:
研究组 & 干预措施
Standard endoscopy (not experimental)
For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
干预措施: Doppler Endoscopic Probe
Doppler treatment (experimental)
A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (\< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
干预措施: Doppler Endoscopic Probe
结局指标
主要结局
The proportion of participants with delayed Post-Polypectomy Induced Ulcer (PPIU) bleeds.
时间窗: Outcome measure will be assessed at 30 days after participants are enrolled.
We will compare the proportion of participants with PPIU bleeding by 30 days follow up in Doppler endoscopic probe (DEP) versus standard treatment. The p value for testing this hypothesis will be computed using Fisher's exact test. The corresponding 95% confidence bounds for the true difference will also be reported.
次要结局
- The total number of hospitalized days.(Outcome measure will be assessed at 30 days after participants are enrolled.)
- The proportion of participants hospitalized.(Outcome measure will be assessed at 30 days after participants are enrolled.)
- The proportion of participants with rectal bleeding reported to us but not severe enough to be hospitalized(Outcome measure will be assessed up to 30 days after enrollment)